Wockhardt: A Formidable Foundation of Trust

Published Online: Wednesday, August 29, 2012
Follow Pharmacy_Times:


Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is a research-based global health care enterprise with relevance in the fields of pharmaceuticals, biotechnology, and a chain of advanced super specialty hospitals.

Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process, and techno-innovation within Wockhardt. At Wockhardt we are looking for new ways of thinking, new ways of working, and new ways to touch people’s lives.

In the field of pharmaceuticals, Wockhardt is gaining a reputation in several parts of the world as a name to trust. Over the past 45 years, starting from its roots in India, Wockhardt has grown to a billion dollar worldwide organization that today spans 14 countries on 5 continents. Over 8000 employees working in offices, more than 14 manufacturing facilities, 4 research centers, and hospitals are completely dedicated to building an important trust in our products.

At Wockhardt, we draw our strength from the formidable foundation of trust built over the years through delivering quality products by continuously investing into R&D and modern manufacturing technologies, as well as contemporary processes. This enables us to deliver world-class quality products. At Wockhardt, we don’t merely formulate medicines, we formulate trust.

We believe that quality medicines begin with strong science, and that the quality of our products is directly related to the integrity of our people. Over 525 Quality Control and Quality Assurance scientists guarantee that Wockhardt’s products, 14 worldwide manufacturing facilities, and 4 research centers meet the strict quality standards set by the FDA. Our world-class global R&D facilities are at the heart of Wockhardt’s pledge and commitment to deliver high-quality medicines at affordable prices, and all are fully compliant with cGMP quality standards.



Wockhardt USA LLC is leading the way in developing the most complete, high-quality line of generic oral solids, liquids, topicals, and injectables available in the United States. Wockhardt USA provides more than 230 NDCs spanning over 77 different product families. We have been producing and distributing quality products in the United States for more than 8 years and have received over 110 ANDA approvals to date.

Wockhardt USA has now become the largest overseas business for Wockhardt, contributing 41% of the global revenue. Wockhardt USA has demonstrated revenue growth of 78% for fiscal year 2011 in the world’s largest and most competitive pharmaceutical market and is geared to derive maximum value from it.

Wockhardt USA’s recent 2012 approvals include Clarithromycin IR Tablets, Fluticasone Nasal Spray, Valacyclovir HCl Caplets, and Carbidopa, Entacapone, Levodopa Oral Tablets. Sixteen additional product launches are anticipated for 2012.

Other key products in the Wockhardt USA product line include Azithromycin Tablets, Divalproex ER Tablets, Enalapril Tablets, Metoprolol Succinate ER Tablets, Nicardipine Injection, Ropinirole HCl Tablets, Ceftriaxone Injection, Tamsulosin Capsules, Hydrocodone and Homatropine Syrup, Megestrol Acetate Oral Suspension, Nystatin Oral Suspension, and Phenytoin Oral Suspension.

For more information, please visit www.wockhardtusa.com

Related Articles
Tighter hydrocodone regulations meant to reduce opioid abuse are hindering pain patients’ access to the products.
Teva Pharmaceutical Industries recently announced that the FDA has accepted for review a New Drug Application for its investigational formulation of extended-release hydrocodone bitartrate with abuse-deterrent properties.
Read about the new generic products featured in February.
The FDA recently accepted for review New Drug Applications for Collegium Pharmaceuticals’ extended-release oxycodone formulation (Xtampza ER) and Pfizer’s extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair of opioid analgesics with abuse-deterrent properties.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$